secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kairos Pharma, LTD. (KAPA)
CIK:        0001962011
Form:       8-K
Filed at:   2025-10-15T23:59:59+00:00
Accession:  0001493152-25-018145
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kairos Pharma grants $950K RSUs to executives; $227.5K cash bonuses for FY2024
------------------------------------------------------------------------------

- Total RSU grant value $950K at $1.31/share, vesting Oct 8, 2026 with change-of-control acceleration.
- CEO John S. Yu receives 190,840 RSUs ($250K) and $87.5K cash bonus for FY2024.
- CSO Neil Bhomick gets 171,756 RSUs ($225K) and $50K cash bonus.
- CFO Doug Samuelson gets 152,672 RSUs ($200K) and $50K bonus; VP R&D Ramachandran Murali also gets 152,672 RSUs ($200K) and $40K.
- Independent directors Hyun Bae, Hansoo Keyoung, Rahul Singhvi each receive 19,084 RSUs worth $25K.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1962011/000149315225018145/0001493152-25-018145-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1962011/000149315225018145/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-018145

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer